(D) Routes of delivery

Case studies. (7) Ocular delivery of peptide and protein drugs

David Harris, Liaw Jia-Horng Liaw, Joseph R. Robinson

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Researchers have identified a number of peptide and protein drugs which may be of benefit in treating conditions of the eye. However, the clinical use of these agents may be limited by their low bioavailabilities of ocular tissues following topical application. Few studies to date have addressed the issue of corneal penetration enhancement of peptides, not least perhaps because of concerns over the local toxicity of such agents. This paper reviews the ocular delivery of peptides and the ocular use of penetration enhancement. Further, it reports a general approach to corneal penetration enhancement based on the principle that epithelial tight junctions, modulated by the cell cytoskeleton, are a major component of the permeability barrier. The cytoskeletal modulator, cytochalasin B, has been shown to give a similar increase in permeability to other conventional penetration enhancers, but with substantially less disruption of epithelial cell membranes. This agent may act via a paracellular cytoskeletally modulated mechanism, which may form a basis for developing relatively specific, low-toxicity corneal penetration enhancers.

Original languageEnglish
Pages (from-to)331-339
Number of pages9
JournalAdvanced Drug Delivery Reviews
Volume8
Issue number2-3
DOIs
Publication statusPublished - Jan 1 1992
Externally publishedYes

Fingerprint

Peptides
Pharmaceutical Preparations
Permeability
Proteins
Cytochalasin B
Tight Junctions
Cytoskeleton
Biological Availability
Epithelial Cells
Research Personnel
Cell Membrane

Keywords

  • Cytochalasin B
  • Cytoskeletal modulator
  • Penetration enhancer
  • Tight junction

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

(D) Routes of delivery : Case studies. (7) Ocular delivery of peptide and protein drugs. / Harris, David; Jia-Horng Liaw, Liaw; Robinson, Joseph R.

In: Advanced Drug Delivery Reviews, Vol. 8, No. 2-3, 01.01.1992, p. 331-339.

Research output: Contribution to journalReview article

@article{15ca6a24ed5f4d919d462c1928a04f3e,
title = "(D) Routes of delivery: Case studies. (7) Ocular delivery of peptide and protein drugs",
abstract = "Researchers have identified a number of peptide and protein drugs which may be of benefit in treating conditions of the eye. However, the clinical use of these agents may be limited by their low bioavailabilities of ocular tissues following topical application. Few studies to date have addressed the issue of corneal penetration enhancement of peptides, not least perhaps because of concerns over the local toxicity of such agents. This paper reviews the ocular delivery of peptides and the ocular use of penetration enhancement. Further, it reports a general approach to corneal penetration enhancement based on the principle that epithelial tight junctions, modulated by the cell cytoskeleton, are a major component of the permeability barrier. The cytoskeletal modulator, cytochalasin B, has been shown to give a similar increase in permeability to other conventional penetration enhancers, but with substantially less disruption of epithelial cell membranes. This agent may act via a paracellular cytoskeletally modulated mechanism, which may form a basis for developing relatively specific, low-toxicity corneal penetration enhancers.",
keywords = "Cytochalasin B, Cytoskeletal modulator, Penetration enhancer, Tight junction",
author = "David Harris and {Jia-Horng Liaw}, Liaw and Robinson, {Joseph R.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0169-409X(92)90007-D",
language = "English",
volume = "8",
pages = "331--339",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - (D) Routes of delivery

T2 - Case studies. (7) Ocular delivery of peptide and protein drugs

AU - Harris, David

AU - Jia-Horng Liaw, Liaw

AU - Robinson, Joseph R.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Researchers have identified a number of peptide and protein drugs which may be of benefit in treating conditions of the eye. However, the clinical use of these agents may be limited by their low bioavailabilities of ocular tissues following topical application. Few studies to date have addressed the issue of corneal penetration enhancement of peptides, not least perhaps because of concerns over the local toxicity of such agents. This paper reviews the ocular delivery of peptides and the ocular use of penetration enhancement. Further, it reports a general approach to corneal penetration enhancement based on the principle that epithelial tight junctions, modulated by the cell cytoskeleton, are a major component of the permeability barrier. The cytoskeletal modulator, cytochalasin B, has been shown to give a similar increase in permeability to other conventional penetration enhancers, but with substantially less disruption of epithelial cell membranes. This agent may act via a paracellular cytoskeletally modulated mechanism, which may form a basis for developing relatively specific, low-toxicity corneal penetration enhancers.

AB - Researchers have identified a number of peptide and protein drugs which may be of benefit in treating conditions of the eye. However, the clinical use of these agents may be limited by their low bioavailabilities of ocular tissues following topical application. Few studies to date have addressed the issue of corneal penetration enhancement of peptides, not least perhaps because of concerns over the local toxicity of such agents. This paper reviews the ocular delivery of peptides and the ocular use of penetration enhancement. Further, it reports a general approach to corneal penetration enhancement based on the principle that epithelial tight junctions, modulated by the cell cytoskeleton, are a major component of the permeability barrier. The cytoskeletal modulator, cytochalasin B, has been shown to give a similar increase in permeability to other conventional penetration enhancers, but with substantially less disruption of epithelial cell membranes. This agent may act via a paracellular cytoskeletally modulated mechanism, which may form a basis for developing relatively specific, low-toxicity corneal penetration enhancers.

KW - Cytochalasin B

KW - Cytoskeletal modulator

KW - Penetration enhancer

KW - Tight junction

UR - http://www.scopus.com/inward/record.url?scp=0026824021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026824021&partnerID=8YFLogxK

U2 - 10.1016/0169-409X(92)90007-D

DO - 10.1016/0169-409X(92)90007-D

M3 - Review article

VL - 8

SP - 331

EP - 339

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 2-3

ER -